BPC-157: what the evidence actually shows
BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice.
Also known as BPC157, Body Protection Compound 157, PL 14736.
Evidence and regulatory status
Animal or laboratory evidence only. No published human trial.
Not approved by the FDA for any indication. Added on 29 September 2023 to category 2 of the 503A bulk drug substances review, the category for substances that may present significant safety risks.
Half-life
No published human pharmacokinetic study reports a half-life for BPC-157. Figures circulating on vendor and forum pages are not traceable to a human trial, so this page does not repeat them.
What published trials used
No published human dosing trial exists for BPC-157.
Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.
How much research exists
- PubMed records
- 228
- Tagged human
- 53
- Clinical trials
- 0
A PubMed search for BPC-157 returns 228 records, of which 53 are tagged as human research and none are typed as a clinical trial.
Counted on . Counts drift, so the exact query is linked rather than described, and you can re-run it.
Common questions
- What is the half-life of BPC-157?
- No published human pharmacokinetic study reports a half-life for injected BPC-157. Figures circulating on vendor sites are not traceable to a human trial, and this page does not repeat them.
- Is BPC-157 FDA approved?
- No. BPC-157 is not approved by the FDA for any use. In 2023 it was placed in category 2 of the 503A bulk substances review, the category for substances with significant safety risks.
- Is there human research on BPC-157?
- A PubMed search returns zero records typed as a clinical trial. The great majority of published BPC-157 research is in rodents. The query is linked above so the count can be re-run.
Sources
- FDA 503A category 2 list · US Food and Drug Administration, 2023
- OPSS advisory · Operation Supplement Safety, US Department of Defense, 2024
Related compounds
Peptides marketed for tissue repair
Grouped by the claim they are sold on rather than by chemistry. They are structurally unrelated: one is a gastric pentadecapeptide, the other a fragment of thymosin beta-4.
- TB-500 TB-500 is a synthetic peptide corresponding to a short fragment of the naturally occurring protein thymosin beta-4.
Others graded preclinical here
Held to the same standard on this site. Each page prints its own literature counts, so where a record is typed as a clinical trial you can see it rather than take our word for the grade.
Planning a schedule?
Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.
Plan a BPC-157 scheduleLast reviewed .